Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Retained Earnings (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Retained Earnings for 15 consecutive years, with $447.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 1433.22% year-over-year to $447.7 million, compared with a TTM value of $447.7 million through Dec 2025, up 1433.22%, and an annual FY2025 reading of $447.7 million, up 1433.22% over the prior year.
  • Retained Earnings was $447.7 million for Q4 2025 at Neurocrine Biosciences, up from $294.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $447.7 million in Q4 2025 and bottomed at -$628.5 million in Q3 2021.
  • Average Retained Earnings over 4 years is -$6.7 million, with a median of $3.3 million recorded in 2024.
  • The sharpest move saw Retained Earnings crashed 19740.62% in 2021, then skyrocketed 1433.22% in 2025.
  • Year by year, Retained Earnings stood at -$628.5 million in 2021, then soared by 101.11% to $7.0 million in 2023, then soared by 317.14% to $29.2 million in 2024, then surged by 1433.22% to $447.7 million in 2025.
  • Business Quant data shows Retained Earnings for NBIX at $447.7 million in Q4 2025, $294.0 million in Q3 2025, and $12.5 million in Q2 2025.